The study is for patients that have been diagnosed with platinum-sensitive high-grade serous ovarian cancer. The investigational drug used in this study is XMT-1536 (upifitamab rilsodotin). The main purpose of the study is to compare progression free survival (the length of time that participants live without their disease getting worse) for participants with ovarian cancer with high NaPi2b level on their tumor cells treated with XMT-1536 versus placebo, following standard chemotherapy. Participants can expect to be in this study for up to 24 months.

This study is for women with endometrial cancer. This study is being done to see if by adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs.

This study is for anyone 18 years or older who provides unpaid care for a loved one living with cancer outside of the hospital setting. The purpose of this study is to help future caregivers and patients by learning how mental fatigue affects caregivers of persons living with cancer and determine if mental fatigue, participating in self-care activities, and general caregiver quality of life are related. Informal caregivers will be invited to complete a confidential, online survey that takes between 25 and 35 minutes to finish. Caregivers who complete the survey may be contacted and asked to participate in a 45-60 minute follow up interview either online or via phone if they are interested. The results of this study will help guide future research to identify ways healthcare professionals can help caregivers handle the stresses of caregiving and provide the best care possible to their loved ones at home.

This study is for women who have endometrial cancer which has grown or has returned after earlier treatment. The purpose of the study is to see if by giving a combination of two experimental drugs or one experimental drug rather than the usual approach can lower the chance of the endometrial cancer growing or spreading by giving a combination of two experimental drugs or one experimental drug rather than the usual approach.

This study is for women with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy and have had prior therapy with bevacizumab.The purpose of the study is to see if the combinations of durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) and cediranib, or olaparib and cediranib keep patients disease free longer than the usual approach.

This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.